ILCN.org (ILCN/WCLC) ILCN.org (ILCN/WCLC)
x/twitter facebook linkedin bluesky youtube instagram iaslc Home
  • Home
  • Featured Topics
    • Diagnostic Oncology
      • Early Detection & Screening
      • Evolving Standards of Care
      • Global Initiatives
    • Meeting News
      • Names & News
      • Nursing & Allied Health
      • Patient Advocacy
    • Radiation Oncology
      • Regulatory News
      • Risk Assessment and Reduction
      • Society News
    • Supportive & Palliative Care
      • Surgical Oncology
      • Tobacco & Smoking Cessation
      • WCLC News
  • WCLC News
  • About Us
Menu
  • Home
  • Featured Topics
    • Diagnostic Oncology
      • Early Detection & Screening
      • Evolving Standards of Care
      • Global Initiatives
    • Meeting News
      • Names & News
      • Nursing & Allied Health
      • Patient Advocacy
    • Radiation Oncology
      • Regulatory News
      • Risk Assessment and Reduction
      • Society News
    • Supportive & Palliative Care
      • Surgical Oncology
      • Tobacco & Smoking Cessation
      • WCLC News
  • WCLC News
  • About Us
loading...
Home Mesothelioma

Real-World Data Shows Less Benefit for Mesothelioma from Checkpoint Inhibitors Vs. Clinical Trials

on: January 27, 2021In: Mesothelioma
Real-World Data Shows Less Benefit for Mesothelioma from Checkpoint Inhibitors Vs. Clinical Trials

Approximately 10% of “real-world” patients with malignant pleural mesothelioma (MPM) benefitted from checkpoint inhibitor therapy with nivolumab, according to the results of a trial presented by Robert A. Belderbos, MD, […] Read more


Real-World Data Show That Survival Just as Good With Carboplatin Therapy as With Cisplatin Therapy in Malignant Pleural Mesothelioma 

Kara Nyberg, PhD
on: January 27, 2021In: Mesothelioma, WCLC 2020 Archive
Real-World Data Show That Survival Just as Good With Carboplatin Therapy as With Cisplatin Therapy in
            Malignant Pleural Mesothelioma 

The largest real-world cohort study of individuals with malignant pleural mesothelioma (MPM) found a median survival duration of 8 months regardless of whether patients received first-line treatment with cisplatin-based chemotherapy […] Read more

SEARCH ILCN

Archives

POPULAR ARTICLES

Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
IASLC Logo
ILCN Editorial Group    IASLC.org   

Advertise with Us   

© 2024 IASLC. All Rights Reserved. Powered By TriStar Event Media, LLC   Privacy Policy